Compare · DVA vs MGRX
DVA vs MGRX
Side-by-side comparison of DaVita Inc. (DVA) and Mangoceuticals Inc. (MGRX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DVA and MGRX operate in Misc Health and Biotechnology Services (Health Care), so they compete in similar markets.
- DVA is the larger of the two at $10.01B, about 1414.9x MGRX ($7.1M).
- Over the past year, DVA is up 8.0% and MGRX is down 75.8% - DVA leads by 83.9 points.
- DVA has hit the wire 3 times in the past 4 weeks while MGRX has been quiet.
- DVA has more recent analyst coverage (12 ratings vs 0 for MGRX).
- Company
- DaVita Inc.
- Mangoceuticals Inc.
- Price
- $151.81-2.06%
- $0.43+8.01%
- Market cap
- $10.01B
- $7.1M
- 1M return
- -2.17%
- +34.71%
- 1Y return
- +8.05%
- -75.84%
- Industry
- Misc Health and Biotechnology Services
- Misc Health and Biotechnology Services
- Exchange
- NYSE
- NASDAQ
- IPO
- 2023
- News (4w)
- 3
- 0
- Recent ratings
- 12
- 0
DaVita Inc.
DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure or end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also provides outpatient, hospital inpatient, and home-based hemodialysis services; owns clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers. In addition, the company provides disease management services; vascular access services; clinical research programs; physician services; and comprehensive care services. As of December 31, 2020, it provided dialysis and administrative services in the United States through a network of 2,816 outpatient dialysis centers serving approximately 204,200 patients; and operated 321 outpatient dialysis centers located in 10 countries outside of the United States serving approximately 36,700 patients. Further, the company provides acute inpatient dialysis services in approximately 900 hospitals and related laboratory services in the United States. The company was formerly known as DaVita HealthCare Partners Inc. and changed its name to DaVita Inc. in September 2016. DaVita Inc. was incorporated in 1994 and is headquartered in Denver, Colorado.
Latest DVA
- SEC Form DEFA14A filed by DaVita Inc.
- SEC Form DEF 14A filed by DaVita Inc.
- DaVita Inc. Schedules 1st Quarter 2026 Investor Conference Call
- Amendment: SEC Form SCHEDULE 13G/A filed by DaVita Inc.
- DaVita Highlights Continued Progress in Value-Based Kidney Care as CKCC Results Show Year-Over-Year Improvement
- Director Arway Pamela M was granted 332 shares, increasing direct ownership by 1% to 26,695 units (SEC Form 4)
- Director Desoer Barbara J was granted 332 shares (SEC Form 4)
- Chief Operating Officer, DKC Maughan David Paul was granted 5,308 shares and covered exercise/tax liability with 13,107 shares, decreasing direct ownership by 6% to 114,467 units (SEC Form 4)
- Director Yale Phyllis R was granted 332 shares, increasing direct ownership by 2% to 14,313 units (SEC Form 4)
- Chief Executive Officer Rodriguez Javier was granted 20,900 shares, increasing direct ownership by 2% to 909,815 units (SEC Form 4)
Latest MGRX
- SEC Form 10-K filed by Mangoceuticals Inc.
- SEC Form NT 10-K filed by Mangoceuticals Inc.
- SEC Form 4 filed by Cohen Jacob D.
- SEC Form 4 filed by Cohen Jacob D.
- Mangoceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Mangoceuticals Announces Lawsuit Seeking Damages Exceeding $73 Million Against Former Technology Consulting and Software Development Firm, Clarity Ventures, Inc.
- Mangoceuticals, Inc. Announces PCT Patent Filing for MGX-0024 Antiviral Technology to Include Inhibiting Respiratory or Orally Acquired Virus Infection in Animals or Birds
- Mangoceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Mangoceuticals' Patented MGX-0024 Achieves Zero Respiratory-Related Mortality in 29,000-Bird Field Trials and Demonstrates Prophylactic Benefit Against H5N1 in Controlled Government Study
- Mangoceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits